Press Releases

2021

May 13, 2021
Amunix Expands its Board of Directors with the Appointment of Industry Veteran, Ciara Kennedy, Ph.D., M.B.A.

April 12, 2021
Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR) Annual Meeting from Lead Program AMX-818 Demonstrating Robust Efficacy in HER2 Tumor Models and Enhanced Safety 

March 4, 2021
Amunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline

January 26, 2021
Amunix Announces the Appointment of Healthcare Investment Banking Veteran Zeeshan Merchant as Chief Financial Officer and Trisha Millican to the Board of Directors

2020

December 9, 2020
Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020

September 17, 2020
Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020

June 22, 2020
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II

May 27, 2020
Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality

March 4, 2020
Amunix Raises $73 Million in Series A Financing Led by Omega Funds

January 10, 2020
Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology

2019

August 27, 2019
Amunix Pharmaceuticals Announces the Appointment of Dr. Maninder Hora as Chief Technical Operations Officer

June, 26, 2019
Amunix Pharmaceuticals Announces the Appointment of Dr. Bryan Irving as Chief Scientific Officer

May 14, 2019
Amunix Expands Executive Team with Appointment of Dr. Mika Derynck as CMO, Dr. Darcy Mootz as CBO, and Yvonne Li as SVP of Finance

January 3, 2019
​Amunix Announces Appointment of Dr. Angie You as Chief Executive Officer and Dr. Rich Heyman as Chairman of the Board of Directors

January 3, 2019
Amunix Announces Licensing Agreement with Merck for ProTIA Immune Activator Platform

2018

May 29, 2018
Amunix announces report by Bioverativ on unprecedented half-life obtained in patients treated with a novel, long-acting FVIII utilizing Amunix’s XTEN® technology

February 20, 2018
Amunix announces XTEN® and ProTIA technology licensing agreement with Celgene

February 13, 2018
Amunix CEO to deliver keynote address on ProTIA, Amunix’s novel immuno-oncology technology, at the Biologics & Biosimilars Congress Europe (March 2018)